These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24167142)

  • 1. [Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34].
    Weng XM; Pan JP
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 42(5):578-82. PubMed ID: 24167142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
    N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
    Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
    Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
    J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis.
    Lumachi F; Ermani M; Camozzi V; Tombolan V; Luisetto G
    Ann N Y Acad Sci; 2009 Sep; 1173 Suppl 1():E60-3. PubMed ID: 19751416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of growth hormone replacement therapy on markers of bone formation and bone mineral density in elderly men].
    Kozakowski J; Papierska L; Krassowski J; Zgliczyński S
    Pol Arch Med Wewn; 1998 Oct; 100(4):306-12. PubMed ID: 10335039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover in passive smoking female rat: relationships to change in bone mineral density.
    Gao SG; Li KH; Xu M; Jiang W; Shen H; Luo W; Xu WS; Tian J; Lei GH
    BMC Musculoskelet Disord; 2011 Jun; 12():131. PubMed ID: 21663694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of bone mineral density in Addison's disease.
    Jódar E; Valdepeñas MP; Martinez G; Jara A; Hawkins F
    Clin Endocrinol (Oxf); 2003 May; 58(5):617-20. PubMed ID: 12699444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The replacement therapy of rPTH(1-84) in established rat model of hypothyroidism].
    Ding Z; Li T; Liu Y; Xiao S
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 50(12):1020-5. PubMed ID: 26888134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between bone formation markers bone alkaline phosphatase, osteocalcin and amino-terminal propeptide of type I collagen and bone mineral density in elderly men. Preliminary results.
    Lumachi F; Orlando R; Fallo F; Basso SM
    In Vivo; 2012; 26(6):1041-4. PubMed ID: 23160690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
    Li YQ; Sun H; Xue D; Xu YC; Li ZD; Wang W; Li PP
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep; 34(9):1064-8. PubMed ID: 25335329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density, osteocalcin, and bone-specific alkaline phosphatase in patients with insulin-dependent diabetes mellitus.
    Lumachi F; Camozzi V; Tombolan V; Luisetto G
    Ann N Y Acad Sci; 2009 Sep; 1173 Suppl 1():E64-7. PubMed ID: 19751417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.